blood sample
Other36 ml of blood sample at D0 and 1 year after transplantation
NCT Number: NCT02843867
The incidence of atherosclerotic complications is increased after kidney transplantation. Traditional risk factors do not fully explain this increased risk. Atherosclerosis is an inflammatory disease in which all players in the immune response are involved. The impact of these immune responses is not well known in immunocompromised patients, particularly among organ transplant. Nevertheless, the work of our group suggest that innate and acquired responses through different mechanisms influencing the evolution of atheromatous disease after transplantation.
The investigators therefore propose to study the impact of the expansion of regulatory T cells on the risk of atherosclerotic complications after transplantation.
Since November 2008, the investigators began a multicenter, prospective study whose purpose is to study in detail the immunological mechanisms of atherosclerosis after transplantation via immunomonitoring cohort of renal transplant patients in the Grand East Interregion. It was planned to include 500 patients and to date a little more than half have been included. After completion of the blood test, the tubes are routed over the Biomonitoring Platform (CIC-BT 506 Besançon) and the samples are stored in CRB Dijon.
The atherosclerotic events are recorded prospectively. The investigators hope to implement as part of ORLY IS, a second study to determine the impact of an expansion of regulatory T cells on the risk of atherosclerotic events.
Our hypothesis is that a cell rate regulatory T below the median results in an increase of 5% of atherosclerotic complications.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Observational
CHU de Besançon, Besançon, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This study is strictly non-interventional, participation in another study is not a cons-indication to the inclusion in this study and no exclusion period is required for inclusion in another study after inclusion in this study (Art L. 1121-12 (loi n°2004-806 du 9 Août 2004).
36 ml of blood sample at D0 and 1 year after transplantation
Time frame: 5 or 10 years
Percentage of regulatory T cells
Time frame: 5 or 10 years
Percentage of regulatory T cells
Time frame: 5 or 10 years
Percentage of regulatory T cells
Centre Hospitalier Universitaire de Besancon
Other
Influence de l'ORientation de la réponse LYmphocytaire Sur la Survenue de Complications athéromateuses après Transplantation rénale (étude ORLY-EST 2)
Acronym: ORLY-Est
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03935958
Cognition Disorders, Cognitive Dysfunction
Chicago, Illinois, United States
View Trial DetailsNCT06584773
Disorder Related to Renal Transplantation
São Paulo, Brazil
View Trial DetailsNCT00905957
Disorder Related to Renal Transplantation, Neurologic Manifestations
Liverpool, Merseyside, United Kingdom
View Trial DetailsNCT01602861
Disorder Related to Renal Transplantation, Fibrosis
Odense C, Denmark
View Trial Details